


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-183004	Application No. 10/671,387
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Neil H. Bander</b>	
		Filing Date <b>September 25, 2003</b>	Group Art Unit <b>1645</b>

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
KAC	AA	4,446,122	05/01/84	Chu et al.			
	AB	4,675,287	06/23/87	Reisfeld et al.			
	AC	4,840,915	06/20/89	Bogoch			
	AD	4,863,851	09/05/89	McEwan et al.			
	AE	4,902,615	2/20/90	Freeman et al.			
	AF	Re. 33,405	10/23/90	Chu et al.			
	AG	4,970,299	11/13/90	Bazinet et al.			
	AH	5,055,404	10/08/91	Ueda et al.			
	AI	5,118,611	06/02/92	Smith et al.			
	AJ	5,130,129	07/14/92	Pardridge			
	AK	5,135,737	08/04/92	Keana			
	AL	5,153,118	10/1992	Wright et al.			
	AM	5,242,824	09/07/93	Hellstrom et al.			
	AN	5,250,297	10/05/93	Grauer et al.			
	AO	5,367,060	11/22/94	Vandlen et al.			
	AP	5,489,525	02/1996	Pastan			
	AQ	5,773,292	06/1998	Bander			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
KAC	AR	WO 94/09150	04/28/94	WIPO				
	AS							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KAC	AT	Bauer, "Clinical Laboratory Methods", 9 <sup>th</sup> ed., St. Louis: C.V. Mosby Company, Chapter 35, <i>Clinical Serology</i> , pp. 1025-1063, 1982.
KAC	AU	Carroll, <i>Clin. Immunol. Immunopathol.</i> , Volume 33, pp. 268-281, 1984.


Examiner Signature  /Karen A. Canella, Ph.D./	Date Considered  05/30/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-183004	Application No. 10/671,387
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Neil H. Bander	
		Filing Date September 25, 2003	Group Art Unit 1645

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KAC	AV	Colcher et al., "Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xerografts in Athymic Mice", <i>Methods in Enzymology</i> , Volume 121, pp. 802-816, 1986.
	AW	Dillman, "Monoclonal Antibodies for Treating Cancer", <i>Annals of Internal Medicine</i> , Volume 111, pp. 592-602, 1989.
	AX	Guinan et al., "An Evaluation of Prostate Specific Antigen in Prostatic Cancer", <i>Journal of Urology</i> , Volume 137, pp. 686-689, 1987.
	AY	Guinan and Rubenstein, "Methods of Early Diagnosis in Genitourinary Cancer", <i>Cancer</i> , Volume 60, pp. 668-676, 1987.
	AZ	Harlow et al., "Antibodies, A Laboratory Manual," Cold Spring Harbor, New York, New York: Cold Spring Harbor Laboratory, Chapter 14, <i>Immunoassays</i> , pp. 553-612, 1988.
	AAA	Leroy et al., "Radioimmunodetection of Lymph Node Invasion in Prostatic Cancer", <i>Cancer</i> , Volume 64, pp. 1-5, 1989.
	ABB	Lopes et al., "Immunohistochemical and Pharmacokinetic Characterization of the Site-Specific Immunoconjugate CYT-356 Derived from Antiprostata Monoclonal Antibody", <i>Cancer Research</i> , Volume 50, pp. 6423-6429, 1990.
	ACC	Raynor et al., "Localization of a Normal Prostatic Secretory Product Using the Monoclonal Antibody, KR-P8", <i>Federation Proceedings</i> , Volume 44, p. 793, 1985.
	ADD	Raynor et al., "Localization of a Normal Prostatic Secretory Product Using the Monoclonal Antibody, KR-P8", <i>Journal of Urology</i> , Volume 134, pp. 384-387, 1985.
	AEE	Raynor et al., "Biochemical Nature of the Prostate-Associated Antigen Identified by the Monoclonal Antibody, KR-P8", <i>The Prostate</i> , Volume 9, pp. 21-31, 1986.
	AFF	Raynor, "Characterization of a monoclonal antibody, KR-P8, that detects a new prostate-specific marker", <i>JNCI</i> , Volume 73, pp. 617-625, 1984.
	AGG	Schlom, In: <i>Molecular Foundations of Oncology</i> , Ch. 6, pp. 97-98, 1991
	AHH	Seaver, "Monoclonal Antibodies In Industry: More Difficult Than Originally Thought", <i>Genetic Engineering News</i> , Volume 14, pp. 10 & 21, 1994.
	AII	Starling et al., "Human Prostate Tissue Antigens Defined by Murine Monoclonal Antibodies", <i>Cancer Research</i> , Volume 46, pp. 367-374, 1986.
	AJJ	Theyer et al., "Role of the MDR-1-Encoded Multiple Drug Resistance Phenotype In Prostate Cancer Cell Lines", <i>The Journal of Urology</i> , Volume 150, pp. 1544-1547, 1993.
	AKK	Troyer et al., "Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate-Specific Membrane Antigen", <i>Urol Oncol</i> , Volume 1, pp. 29-37, 1995.
	ALL	Troyer et al., "Location of Prostate-Specific Membrane Antigen in the LNCaP Prostate Carcinoma Cell Line", <i>The Prostate</i> , Volume 30, pp. 232-242,
	AMM	Vitetta et al., "Redesigning Nature's Poisons To Create Anti-Tumor Reagents", <i>Science</i> , Volume 238, pp. 1098-1104, 1987.
	ANN	Waldman, "Monoclonal Antibodies in Diagnosis and Therapy", <i>Science</i> , Volume 252, pp. 1657-1662, 1991.
	AOO	Ware, "Production of monoclonal antibody alpha Pro3 recognizing a human prostatic carcinoma antigen" <i>Cancer Research</i> , Vol. 42, pp. 1215-1222, 1982.
	APP	Webb, <i>Cancer Immunol Immunother.</i> , Volume 17, pp. 7-17, 1984.

Examiner Signature /Karen A. Canella, Ph.D./	Date Considered 05/30/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 3 of 3Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
10448-183004Application No.  
10/671,387**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Neil H. BanderFiling Date  
September 25, 2003Group Art Unit  
1645**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
KAC	AQQ	Wright et al., International Journal of Cancer, Vol. 47, pp. 717-725, 1991
↓	ARR	Wright et al., "Expression of Prostate-Specific Membrane Antigen in Normal, Benign, and Malignant Prostate Tissues", <i>Urol Oncol</i> , Volume 1, pp. 18-28, 1995.
↓	ASS	Wynant et al., Prostate, Vol. 18, pp. 229-241, 1991
↓	ATT	International Search Report, August 2, 2002.

Examiner Signature


/Karen A. Canella, Ph.D./

Date Considered

05/30/2006

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Sheet 1 of 1

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-183004	Application No. 10/671,387
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Neil H. Bander	
		Filing Date September 25, 2003	Group Art Unit 1645

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KAC	AC	Bander, "Current Status of Monoclonal Antibodies for Imaging and Therapy of Prostate Cancer" <i>Semin. in Oncology</i> 21:607-612, 1994.
	AD	

Examiner Signature /Karen A. Canella, Ph.D./	Date Considered 05/30/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)